Overview

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Status:
Terminated

Trial end date:
2019-06-25

Target enrollment:

Participant gender:

Summary

The primary objectives are: Phase 1b: - To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules. - To evaluate safety and tolerability Phase 2: - To estimate the overall response rate (ORR). - To evaluate safety and tolerability

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Amgen
Onyx Therapeutics, Inc.

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate